Masoud Amiri
1, Hamid Nasri
2*1 Social Health Determinants Research Center, Shahrekord University of Medical Sciences Shahrekord, Iran.
2 Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Implication for health policy/practice/research/medical education
Secondary hyperparathyroidism is a progressive disease common in patients with chronic renal failure and with serious concerns for patient health. If unsuccessfully controlled, secondary hyperparathyroidism develops and can lead to soft tissue calcification, bone disease, and vascular calcification, which adversely impact mortality and morbidity. Conventional therapies that target vitamin D and phosphorous levels are not without disadvantages. The appearance of the calcimimetics and a better understanding of the strengths and limitations of native and active vitamin D compounds have advanced the treatment options for patients with secondary hyperparathyroidism.
Please cite this paper as: Amiri M, Nasri H. Secondary Hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyr Dis 2014; 2(1): 1-2.